{"transactions":[{"id":741484,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T22:04:03.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":14677,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date."}],"balance_after":14677,"derivative":{"exercise_price":10.59,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":14677},"source":{"system":"sec-edgar","filing":"0001193125-26-268006","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377759/000119312526268006/ownership.xml","form_type":"4"}},{"id":1113164,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:29:03.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":6010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date."}],"balance_after":6010,"derivative":{"exercise_price":14.87,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":6010},"source":{"system":"sec-edgar","filing":"0000950170-25-085455","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377759/000095017025085455/ownership.xml","form_type":"4"}},{"id":1481936,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-12T21:17:55.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":5190,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date."}],"balance_after":5190,"derivative":{"exercise_price":42.19,"expiration_date":"2034-06-10","underlying":"Common Stock","underlying_shares":5190},"source":{"system":"sec-edgar","filing":"0000950170-24-072557","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377759/000095017024072557/ownership.xml","form_type":"4"}},{"id":1747604,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-08T02:15:43.000Z","date":"2023-11-03","kind":"grant","planned":false,"acquired":true,"shares":24712,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Korro common stock issued under the Korro Bio, Inc. 2019 Stock Incentive Plan (the \"2019 Plan\") was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable under the 2019 Plan prior to the Merger, as adjusted for the exchange ratio and the reverse stock split."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Korro common stock issued under the Korro Bio, Inc. 2019 Stock Incentive Plan (the \"2019 Plan\") was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable under the 2019 Plan prior to the Merger, as adjusted for the exchange ratio and the reverse stock split."},{"field":"shares","element":"transactionShares","label":"F2","text":"Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Korro common stock issued under the Korro Bio, Inc. 2019 Stock Incentive Plan (the \"2019 Plan\") was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable under the 2019 Plan prior to the Merger, as adjusted for the exchange ratio and the reverse stock split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Korro common stock issued under the Korro Bio, Inc. 2019 Stock Incentive Plan (the \"2019 Plan\") was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable under the 2019 Plan prior to the Merger, as adjusted for the exchange ratio and the reverse stock split."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Received in exchange for a stock option to acquire 497,347 shares of Legacy Korro common stock issued under the 2019 Plan pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to the option vest in 48 equal monthly installments commencing from August 14, 2022, subject to the Reporting Person's continued service on each such vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Korro common stock issued under the Korro Bio, Inc. 2019 Stock Incentive Plan (the \"2019 Plan\") was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable under the 2019 Plan prior to the Merger, as adjusted for the exchange ratio and the reverse stock split."}],"balance_after":24712,"derivative":{"exercise_price":20.94,"expiration_date":"2033-02-08","underlying":"Common Stock","underlying_shares":24712},"source":{"system":"sec-edgar","filing":"0000950170-23-060608","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377759/000095017023060608/ownership.xml","form_type":"4"}},{"id":1747603,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-08T02:15:43.000Z","date":"2023-11-03","kind":"grant","planned":false,"acquired":true,"shares":67061,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Korro common stock issued under the Korro Bio, Inc. 2019 Stock Incentive Plan (the \"2019 Plan\") was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable under the 2019 Plan prior to the Merger, as adjusted for the exchange ratio and the reverse stock split."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Korro common stock issued under the Korro Bio, Inc. 2019 Stock Incentive Plan (the \"2019 Plan\") was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable under the 2019 Plan prior to the Merger, as adjusted for the exchange ratio and the reverse stock split."},{"field":"shares","element":"transactionShares","label":"F2","text":"Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Korro common stock issued under the Korro Bio, Inc. 2019 Stock Incentive Plan (the \"2019 Plan\") was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable under the 2019 Plan prior to the Merger, as adjusted for the exchange ratio and the reverse stock split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Korro common stock issued under the Korro Bio, Inc. 2019 Stock Incentive Plan (the \"2019 Plan\") was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable under the 2019 Plan prior to the Merger, as adjusted for the exchange ratio and the reverse stock split."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in exchange for a stock option to acquire 1,349,645 shares of Legacy Korro common stock issued under the 2019 Plan pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option are fully vested and immediately exercisable."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Korro common stock issued under the Korro Bio, Inc. 2019 Stock Incentive Plan (the \"2019 Plan\") was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable under the 2019 Plan prior to the Merger, as adjusted for the exchange ratio and the reverse stock split."}],"balance_after":67061,"derivative":{"exercise_price":11.68,"expiration_date":"2030-08-13","underlying":"Common Stock","underlying_shares":67061},"source":{"system":"sec-edgar","filing":"0000950170-23-060608","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377759/000095017023060608/ownership.xml","form_type":"4"}},{"id":1747602,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-08T02:15:43.000Z","date":"2023-11-03","kind":"grant","planned":false,"acquired":true,"shares":35114,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Received in exchange for 706,702 shares of common stock of Korro Bio Ops, Inc. (f/k/a Korro Bio, Inc., \"Legacy Korro\") pursuant to an Agreement and Plan of Merger dated as of July 14, 2023 (the \"Merger Agreement\") by and among Legacy Korro, the Issuer (f/k/a Frequency Therapeutics, Inc.) and Frequency Merger Sub, Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"). Under the terms of the Merger Agreement, on November 3, 2023, Merger Sub merged with and into Legacy Korro (the \"Merger\"), with Legacy Korro surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Korro common stock was converted into the right to receive 0.049688 of a share of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-50. Subsequent to the Merger, the name of the Issuer was changed from Frequency Therapeutics, Inc. to Korro Bio, Inc."},{"field":"shares","element":"transactionShares","label":"F1","text":"Received in exchange for 706,702 shares of common stock of Korro Bio Ops, Inc. (f/k/a Korro Bio, Inc., \"Legacy Korro\") pursuant to an Agreement and Plan of Merger dated as of July 14, 2023 (the \"Merger Agreement\") by and among Legacy Korro, the Issuer (f/k/a Frequency Therapeutics, Inc.) and Frequency Merger Sub, Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"). Under the terms of the Merger Agreement, on November 3, 2023, Merger Sub merged with and into Legacy Korro (the \"Merger\"), with Legacy Korro surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Korro common stock was converted into the right to receive 0.049688 of a share of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-50. Subsequent to the Merger, the name of the Issuer was changed from Frequency Therapeutics, Inc. to Korro Bio, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 706,702 shares of common stock of Korro Bio Ops, Inc. (f/k/a Korro Bio, Inc., \"Legacy Korro\") pursuant to an Agreement and Plan of Merger dated as of July 14, 2023 (the \"Merger Agreement\") by and among Legacy Korro, the Issuer (f/k/a Frequency Therapeutics, Inc.) and Frequency Merger Sub, Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"). Under the terms of the Merger Agreement, on November 3, 2023, Merger Sub merged with and into Legacy Korro (the \"Merger\"), with Legacy Korro surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Korro common stock was converted into the right to receive 0.049688 of a share of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-50. Subsequent to the Merger, the name of the Issuer was changed from Frequency Therapeutics, Inc. to Korro Bio, Inc."}],"balance_after":35114,"source":{"system":"sec-edgar","filing":"0000950170-23-060608","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377759/000095017023060608/ownership.xml","form_type":"4"}},{"id":1960848,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-09T14:12:38.000Z","date":"2023-03-08","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"kind","element":"transactionCoding","label":"F3","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"kind","element":"transactionCoding","label":"F4","text":"(Continued on footnote 3) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued on footnote 3) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued on footnote 3) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."}],"balance_after":0,"derivative":{"exercise_price":3.41,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-23-007657","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1377759/000089924323007657/doc4.xml","form_type":"4"}},{"id":1960847,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-09T14:12:38.000Z","date":"2023-03-08","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"kind","element":"transactionCoding","label":"F3","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"kind","element":"transactionCoding","label":"F4","text":"(Continued on footnote 3) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued on footnote 3) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued on footnote 3) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."}],"balance_after":0,"derivative":{"exercise_price":6.88,"expiration_date":"2031-06-04","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-23-007657","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1377759/000089924323007657/doc4.xml","form_type":"4"}},{"id":1960846,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-09T14:12:38.000Z","date":"2023-03-08","kind":"disposition_to_issuer","acquired":false,"shares":34111,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"kind","element":"transactionCoding","label":"F3","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"kind","element":"transactionCoding","label":"F4","text":"(Continued on footnote 3) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued on footnote 3) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued on footnote 3) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."}],"balance_after":0,"derivative":{"exercise_price":16.62,"expiration_date":"2028-04-01","underlying":"Common Stock","underlying_shares":34111},"source":{"system":"sec-edgar","filing":"0000899243-23-007657","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377759/000089924323007657/doc4.xml","form_type":"4"}},{"id":1960845,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-09T14:12:38.000Z","date":"2023-03-08","kind":"disposition_to_issuer","acquired":false,"shares":6328,"price":7.12,"value":45055.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated June 22, 2022 (the \"Merger Agreement\"), by and among the Issuer, Sino Biopharmaceutical Limited, Fennec Acquisition Incorporated (\"Parent\"), and invoX Pharma Limited (\"Purchaser\"), including the completion on March 8, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $7.12 per share in cash, without interest, less any required withholding taxes (the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Purchaser on March 8, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Each Company RSU (as defined in the Merger Agreement) that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash equal to the product of (a) the total number of Shares (as defined the Merger Agreement) issuable in settlement of such Company RSU immediately prior to the Effective Time without regard to vesting multiplied by (b) the Merger Consideration (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated June 22, 2022 (the \"Merger Agreement\"), by and among the Issuer, Sino Biopharmaceutical Limited, Fennec Acquisition Incorporated (\"Parent\"), and invoX Pharma Limited (\"Purchaser\"), including the completion on March 8, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $7.12 per share in cash, without interest, less any required withholding taxes (the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Purchaser on March 8, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each Company RSU (as defined in the Merger Agreement) that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash equal to the product of (a) the total number of Shares (as defined the Merger Agreement) issuable in settlement of such Company RSU immediately prior to the Effective Time without regard to vesting multiplied by (b) the Merger Consideration (as defined in the Merger Agreement)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-007657","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377759/000089924323007657/doc4.xml","form_type":"4"}},{"id":1960844,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-09T14:12:38.000Z","date":"2023-03-08","kind":"other","acquired":false,"shares":97547,"price":7.12,"value":694534.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated June 22, 2022 (the \"Merger Agreement\"), by and among the Issuer, Sino Biopharmaceutical Limited, Fennec Acquisition Incorporated (\"Parent\"), and invoX Pharma Limited (\"Purchaser\"), including the completion on March 8, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $7.12 per share in cash, without interest, less any required withholding taxes (the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Purchaser on March 8, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated June 22, 2022 (the \"Merger Agreement\"), by and among the Issuer, Sino Biopharmaceutical Limited, Fennec Acquisition Incorporated (\"Parent\"), and invoX Pharma Limited (\"Purchaser\"), including the completion on March 8, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $7.12 per share in cash, without interest, less any required withholding taxes (the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Purchaser on March 8, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price."}],"balance_after":6328,"source":{"system":"sec-edgar","filing":"0000899243-23-007657","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377759/000089924323007657/doc4.xml","form_type":"4"}},{"id":2224000,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-06-22T21:11:42.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were granted under the Issuer's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares under the award shall vest in 12 equal monthly installments over a one-year period through June 16, 2023, subject to the Reporting Person's continued service as a director of the company."}],"balance_after":20000,"derivative":{"exercise_price":3.41,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-038714","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377759/000120919122038714/doc4.xml","form_type":"4"}},{"id":2592121,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-24T22:34:09.000Z","date":"2020-11-20","kind":"grant","acquired":true,"shares":16875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This amendment to the Form 4 filed on November 24, 2020 is being filed solely to report the ownership of the restricted stock units (\"RSUs\") received by the Reporting Person in Table I of this Form 4 rather than in Table II as originally reported. No additional grants of securities are reported hereby."},{"field":"shares","element":"transactionShares","label":"F2","text":"The securities awarded are in the form of RSUs. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five per cent (25%) of the total number of shares under the award shall vest on the first anniversary of the \"Vesting Commencement Date,\" July 1, 2020, and two and one twelfth per cent (2.083%) of the total number of shares under the award shall vest monthly thereafter, provided in each case that the Reporting Person remains a service provider of the Issuer continuously from the Vesting Commencement Date to the relevant date."}],"balance_after":16875,"source":{"system":"sec-edgar","filing":"0001209191-21-053233","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377759/000120919121053233/doc4a.xml","form_type":"4/A","original_submission_date":"2020-11-24"}},{"id":2679116,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2021-06-07T20:12:18.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were granted under the Issuer's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares under the award shall vest in 12 equal monthly installments over a one-year period through June 4, 2022, subject to the Reporting Person's continued service as a director of the company."}],"balance_after":20000,"derivative":{"exercise_price":6.88,"expiration_date":"2031-06-04","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-21-038563","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377759/000120919121038563/doc4.xml","form_type":"4"}},{"id":2885307,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-02T21:17:07.000Z","date":"2021-02-01","kind":"grant","acquired":true,"shares":87000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The securities awarded are in the form of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. 68% of the RSUs vested immediately on the transaction date; 32% shall vest on the one-year anniversary of the transaction date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"All share numbers reported are RSUs."}],"balance_after":103875,"source":{"system":"sec-edgar","filing":"0001209191-21-006741","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377759/000120919121006741/doc4.xml","form_type":"4"}},{"id":2967847,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-11-24T23:56:59.000Z","date":"2020-11-20","kind":"grant","acquired":true,"shares":16875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"This option was issued in replacement of an option to purchase shares of F-star Therapeutics Limited."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Twenty-five per cent (25%) of the total number of Shares under Award shall vest on the first anniversary of the Vesting Commencement Date, July 1, 2020, and two and one twelfth per cent (2.083%) of the total number of Shares under Award shall vest monthly thereafter, provided in each case that the Participant remains a Service Provider continuously from the Vesting Commencement Date to the relevant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Twenty-five per cent (25%) of the total number of Shares under Award shall vest on the first anniversary of the Vesting Commencement Date, July 1, 2020, and two and one twelfth per cent (2.083%) of the total number of Shares under Award shall vest monthly thereafter, provided in each case that the Participant remains a Service Provider continuously from the Vesting Commencement Date to the relevant date."}],"balance_after":16875,"derivative":{"underlying":"Common Stock","underlying_shares":16875},"source":{"system":"sec-edgar","filing":"0001209191-20-060342","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377759/000120919120060342/doc4.xml","form_type":"4"}},{"id":2967846,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-11-24T23:56:59.000Z","date":"2020-11-20","kind":"grant","acquired":true,"shares":34111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This option was issued in replacement of an option to purchase shares of F-star Therapeutics Limited."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"So long as Participant remains continuously a Service Provider 28% of the total number of Shares under Award shall vest on the first anniversary of the Vesting Commencement Date, April 1, 2018, and 2% of the total number of Shares under Award shall vest monthly thereafter."}],"balance_after":34111,"derivative":{"exercise_price":16.62,"expiration_date":"2028-04-01","underlying":"Common Stock","underlying_shares":34111},"source":{"system":"sec-edgar","filing":"0001209191-20-060342","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377759/000120919120060342/doc4.xml","form_type":"4"}},{"id":4131843,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2017-12-14T21:07:28.000Z","date":"2017-12-12","kind":"grant","acquired":true,"shares":292500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on December 12, 2017 with respect to 292,500 shares of Common Stock, with 25% vesting on December 12, 2018 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":292500,"derivative":{"exercise_price":18.295,"expiration_date":"2027-12-11","underlying":"Common Stock","underlying_shares":292500},"source":{"system":"sec-edgar","filing":"0001209191-17-065659","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919117065659/doc4.xml","form_type":"4"}},{"id":4137991,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2017-12-08T22:27:16.000Z","date":"2017-12-08","kind":"sale","acquired":false,"shares":94143,"price":20.821,"value":1960151.403,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $20.51 to $21.48. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price."}],"balance_after":458250,"source":{"system":"sec-edgar","filing":"0001209191-17-064786","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919117064786/doc4.xml","form_type":"4"}},{"id":4137990,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2017-12-08T22:27:16.000Z","date":"2017-12-07","kind":"sale","acquired":false,"shares":27566,"price":21.4572,"value":591489.1752,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $21.33 to $21.65. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price."}],"balance_after":552393,"source":{"system":"sec-edgar","filing":"0001209191-17-064786","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919117064786/doc4.xml","form_type":"4"}},{"id":4137989,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2017-12-08T22:27:16.000Z","date":"2017-12-07","kind":"sale","acquired":false,"shares":103574,"price":21.0514,"value":2180377.7036,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $20.33 to $21.32. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price."}],"balance_after":579959,"source":{"system":"sec-edgar","filing":"0001209191-17-064786","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919117064786/doc4.xml","form_type":"4"}},{"id":4137988,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2017-12-08T22:27:16.000Z","date":"2017-12-06","kind":"sale","acquired":false,"shares":12467,"price":20.8398,"value":259809.7866,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $20.70 to $21.12. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price."}],"balance_after":683533,"source":{"system":"sec-edgar","filing":"0001209191-17-064786","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919117064786/doc4.xml","form_type":"4"}},{"id":4137987,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2017-12-08T22:27:16.000Z","date":"2017-12-06","kind":"sale","acquired":false,"shares":99033,"price":20.278,"value":2008191.174,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan.  The price reflected is the average price per share for the transactions that are aggregated and reported on the line.  Shares ranged in price from $19.70 to $20.69.  The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price."}],"balance_after":696000,"source":{"system":"sec-edgar","filing":"0001209191-17-064786","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919117064786/doc4.xml","form_type":"4"}},{"id":4293036,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2017-06-05T11:53:44.000Z","date":"2017-06-01","kind":"grant","acquired":true,"shares":8400,"price":11.9499,"value":100379.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.88 to $12.05, inclusive."}],"balance_after":795033,"source":{"system":"sec-edgar","filing":"0001209191-17-037510","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919117037510/doc4.xml","form_type":"4"}},{"id":4494099,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":39214,"kind":"person","name":"Bermingham Nessan","position":1,"cik":"0001377759","reported_name":"Bermingham Nessan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2017-01-11T01:03:11.000Z","date":"2017-01-06","kind":"grant","acquired":true,"shares":270000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 6, 2017 with respect to 270,000 shares of Common Stock, with 25% vesting on January 6, 2018 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":270000,"derivative":{"exercise_price":13.88,"expiration_date":"2027-01-05","underlying":"Common Stock","underlying_shares":270000},"source":{"system":"sec-edgar","filing":"0001209191-17-003282","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919117003282/doc4.xml","form_type":"4"}}]}